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A B S T R A C T
Blockade of platelet adenosine-diphosphate (ADP) receptors has been established 
as a key therapeutic strategy in cardiovascular disease. Among the thienopyridines, 
clopidogrel decreases ischemic outcome in patients who present with acute coronary 
syndromes and the more potent prasugrel has been demonstrated to be superior to 
clopidogrel in patients who are scheduled to undergo percutaneous coronary inter-
vention. However, the antiplatelet potency is also associated with an increased risk of 
bleeding complications, and the irreversible ADP receptor antagonism has potential 
implications especially in the setting of coronary by-pass operation. Ticagrelor is a 
new reversible antagonist of the P2Y12 receptor, which seems to be more effective 
and at the same time equally safe to the so far established antiplatelet regimens. This 
article reviews the current data on this novel compound focusing on its advantageous 
pharmacology and the clinical results provided by the first phase IIb and III trials.
I N T R O D U C T I O N
Oral antiplatelet therapy with platelet P2Y12 antagonists, primarily the thienopy-
ridine clopidogrel, is a major strategy for preventing cardiovascular events in patients 
with acute coronary syndromes (ACS) and those undergoing percutaneous coronary 
intervention. Nevertheless, limitations of clopidogrel include the requirement for 
metabolic conversion to its active metabolite, leading to slow onset of its effect, and 
irreversible binding of the active metabolite to the P2Y12 receptor, which precludes 
recovery of platelet function as well as generally low and variable levels of platelet 
inhibition that may be associated with the risk of adverse clinical events. 1-3 The new 
thienopyridine, prasugrel, is metabolized to its active form more efficiently than 
clopidogrel and produces higher levels of platelet inhibition but this benefit has been 
accompanied by an increased risk of major bleeding. 4 Thus, despite the active research 
on platelet inhibition, the need for more potent and safer antiplatelet agents is still 
present. Ticagrelor is a new reversible P2Y12 antagonist with favourable pharmaco-
logic characteristics. The results from the first phase III trial evaluating its efficacy 
and safety are encouraging.
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P H A R M A C O K I N E T I C S -
P H A R M A C O D Y N A M I C S
Ticagrelor (AZD6140) is a member of a new chemical 
class of antiplatelet agents termed cyclopentyl-triazolopyri-
midines (Fig. 1). It is the first oral agent which binds P2Y12 
receptor reversibly5. Unlike thienopyridines, ticagrelor does 
not require metabolic conversion to an active form (Table 1). 
The metabolite AR-C124910XX has a similar potency with 
the parent compound in inhibiting the P2Y12 receptor 6. AR- 
124910XX is rapidly formed [time to peak plasma concentra-
tion (tmax) 1.3–2 h] by cytochrome P4503A. Both ticagrelor 
and ARC124910XX are mainly excreted in faeces and renal 
clearance is of minor importance.7 Ticagrelor binds rapidly 
to the P2Y12 receptor8,9 and notably, this binding was shown 
to be reversible, with the offset of effect following declining 
plasma concentrations. In detail, ticagrelor binds to the P2Y12 
receptor at a site distinct from the ADP binding site, inhibits 
ADP-induced receptor signalling in a non-competitive man-
ner with ADP and has greater affinity for the receptor and 
greater potency in platelet inhibition than thienopyridines 
such as clopidogrel and prasugrel. Within 30 min, a ticagrelor 
loading dose of 180 mg resulted in roughly the same level of 
inhibition of platelet aggregation as that achieved 8 h after a 
clopidogrel loading dose of 600 mg.10-12
Following the administration of 1.0, 3.0, 10, 30, 100, 200, 
300 and 400 mg ticagrelor, absorption of the drug was rapid, 
with the median tmax ranging from 1.3 to 2.0 h. The formation of 
the active metabolite, AR-C124910XX, was also rapid (median FIGURE 1. Chemical structure of ticagrelor.
TABLE 1. Basic characteristics of P2Y12 inhibitors
Ticagrelor Prasugrel Clopidogrel
Drug nature The first of a new class of 
orally active non-thienopy-
ridine antiplatelet agents: 
cyclopentyltriazolopyrimidines
3rd generation thienopyridine 2nd generation thienopyridine
Mechanism of action Reversible inhibitor of the 
adenosine diphosphate (ADP) 
P2Y12 receptor
Irreversible inhibitor of the 
adenosine diphosphate (ADP)
P2Y12 receptor
Irreversible inhibitor of the 
adenosine diphosphate (ADP)
P2Y12 receptor 
Active substance
drug/metabolite
Both drug and its metabolite
are active
Drug is inactive and needs to be 
metabolized to active metabolites
Drug is inactive and needs to be 
metabolized to active metabolites
Time to achieve 
maximum platelet 
inhibition or 
maximum plasma 
concentration
After loading dose 180
mg the maximum plasma
concentrations and maximum
platelet inhibition are
reached in 1–3 h 
After loading dose 60 mg the 
maximum 60-70% platelet inhibition 
is usually achieved 2-4 h, maximum 
plasma concentrations of active 
metabolite is reached within 0.5 h
After loading dose 600 mg the 
maximum plasma
concentrations is achieved in 1 h 
and maximum platelet inhibition is 
within 2–3 h
The mean elimination
half-life
The mean elimination
half-life is 6 to 13 h (dose
independent)
The mean elimination
half-life of active metabolite is 3.7 h
After a single of 75 mg dose half-
life is approximately 6 h. The 
elimination half-life of the inactive 
acid metabolite is 8 h after single 
and repeated dose
Elimination No specific data Approximately 70% of prasugrel 
metabolites are eliminated by the 
kidney
Approximately 40% of a 75 mg dose 
is excreted in urine and 35–60% is 
excreted in faeces
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tmax 1.5–3.0 h) At doses ≥30 mg, the mean t½ was 7.1–8.5 h for 
ticagrelor and 8.5–10.1 h for AR-C124910XX. The inhibition 
of ADP-induced platelet aggregation, as assessed by opti-
cal aggregometry, was found to be dose-related following a 
single oral dose of ticagrelor demonstrated a rapid (by 2 h), 
dose-related (up to 100 mg ticagrelor) and almost complete 
final-extent inhibition of platelet activation [IPA] (at doses 
of ≥100 mg); the IPA did not increase further at doses >100 
mg due to near complete inhibition). No marked inhibition of 
platelet aggregation was observed at ticagrelor doses <30 mg. 
The ticagrelor-mediated IPA was reversible, since a lessening 
of inhibition, based on observed decreases in IPA from peak 
levels, was evident by 12 and 24 h after dosing as active moiety 
concentrations were reduced in the plasma. Following a single 
oral dose of ticagrelor, the pharmacokinetics of ticagrelor and 
its metabolite were linear.13
In animal models, ticagrelor was compared with a chemi-
cal compound indistinguishable from the active metabolite 
of prasugrel, and it exhibited greater affinity for the P2Y12 
receptor and greater potency in inhibiting ADP-induced 
receptor signaling/aggregatory response. The difference in 
pharmacodynamics in terms of binding irreversibility indi-
cates a greater separation between antithrombotic effect and 
bleeding effect for the reversible inhibition.14
The ONSET/OFFSET Study was designed to determine 
the onset and offset of the antiplatelet effect of ticagrelor 
with the PLATO trial dose compared with high-loading-
dose clopidogrel and placebo in stable patients with coronary 
heart disease given background aspirin therapy. A total of 23 
patients were randomized in a double-blind fashion to clopi-
dogrel (600 mg loading dose, 75 mg/day maintenance dose), 
ticagrelor (180 mg loading dose, 90 mg twice a day mainte-
nance dose), or placebo for six weeks. A 10-day drug-offset 
period followed. Several platelet aggregation parameters were 
assessed such as: platelet aggregation induced by ADP (20 and 
5 μmol/L), collagen 2 μg/mL, and arachidonic acid 2 mmol/L 
in platelet-rich plasma, platelet aggregation in whole blood, 
ADP-stimulated (5 μmol/L, final concentration) expression 
of glycoprotein, IIb/IIIa receptors and P-selectin. Moreover, 
measurement of vasodilator-stimulated phosphoprotein phos-
phorylation (VASP-P) was performed which is a method of 
quantifying P2Y12 receptor reactivity and reflects the extent 
of P2Y12 receptor blockade.
The primary end point for onset was IPA (20 μmol/L ADP, 
final extent) at 2 hours after the first dose; for offset, it was 
the slope of IPA between 4 and 72 hours after the last dose 
of study drug. Secondary pharmacodynamic end points were 
IPA (final and maximal extent), measured by 5- and 20-μmol/L 
ADP– and 2μg/mL collagen–induced light-transmittance ag-
gregometry, ADP induced glycoprotein IIb/IIIa and P-selectin 
expression along with other sophisticated aggregation indices. 
The primary end point for onset, IPA at 2 hours after loading 
was greater for ticagrelor than for clopidogrel (88% vs 38%, 
p=0.0001). In fact, within 1 hour of ticagrelor loading, IPA 
was greater than the maximum IPA achieved after clopidogrel 
loading. The mean time to maximum IPA in the ticagrelor 
group was 5.8 hours less than that required for clopidogrel. 
The rate of onset (slope) of the antiplatelet effect curve from 
0 to 2 hours after the loading dose was also greater in the 
ticagrelor group (43.57 versus 19.45 IPA %/h, p=0.0001). By 2 
hours after loading, a greater proportion of patients receiving 
ticagrelor achieved >50% IPA (98% vs 31%, p=0.0001) and 
>70% IPA (90% vs 16%, p=0.0001).
At the end of the 6 weeks of treatment, IPA was signifi-
cantly higher in the ticagrelor group. The ticagrelor group had 
significantly lower IPA at 72 and 120 hours after the last dose 
(p0.05), and the IPA did not differ thereafter between the 
groups. The rate of offset (slope) of the antiplatelet effect curve 
from 4 to 72 hours after the last dose, which was the primary 
end point for offset, was greater in the ticagrelor than in the 
clopidogrel group (-1.04 vs -0.48 IPA %/h, p<0.0001). IPA 
for ticagrelor on day 3 after the last dose was comparable to 
that for clopidogrel at day 5 and IPA on day 5 for ticagrelor 
were similar to clopidogrel on day 7 and did not differ from 
placebo. Bleeding rates were greater with ticagrelor adminis-
tration (28% vs 13%) but no major haemorrhages were noted 
in the study. 12
C L I N I C A L  S T U D I E S
The DISPERSE (Dose confirmation Study assessing anti- 
Platelet Effects of AZD6140 vs clopidogrel in non–ST segment 
Elevation myocardial infarction)-2 trial was a randomized, 
double-blind, double-dummy trial conducted to assess the 
safety, tolerability, and initial efficacy of AZD6140 plus aspirin 
in comparison with clopidogrel plus aspirin in patients with 
non–ST-segment elevation ACS. A number of 990 eligible 
patients were randomized to receive AZD6140 90 mg or180 mg 
twice daily, subrandomized to receive or not an initial loading 
dose of 270 mg, or clopidogrel 300 mg followed by 75 mg once 
daily for up to 3 months, in a 1:1:1 double-blind manner.
The primary end-point, major or minor bleeding at 4 
weeks, was not different among the 3 groups (9.8% vs 8.0% 
vs 8.1%, p=0.43 and p= 0.96 vs. clopidogrel, respectively). No 
statistical significance was noted in the differences of the rates 
of “major - fatal/life-threatening” bleeding or “major - other” 
bleeding. Major bleeding in the first 48 hours, reflecting the 
effect of the loading doses, was also not statistically significant 
among all groups. Moreover, the rates of death and cardiovas-
cular death were similar between clopidogrel and ticagrelor 
treated patients although the small number of clinical events 
did not allow reliable conclusions regarding the efficacy of 
AZD6140 versus clopidogrel to be extracted. Notably, a nu-
merically lower rate of bleeding in ticagrelor receiving patients 
undergoing CABG between 1 and 5 days after stopping study 
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drug was observed, which could be attributed to a recovery of 
platelet function due to the reversible binding of AZD6140 to 
the P2Y12 receptor.15
The PLATelet inhibition and patient Outcomes (PLATO) 
trial was a phase III multicenter, double-blind, randomized 
trial comparing ticagrelor with clopidogrel on top of aspirin 
treatment, in patients admitted to the hospital due to an ACS 
with or without ST segment elevation. Ticagrelor was given at 
a loading dose of 180 mg followed by a dose of 90 mg twice 
daily. Clopidogrel was administered at a 300-mg loading 
dose followed by a dose of 75 mg daily. Patients undergoing 
PCI after randomization received, in a blind fashion, an ad-
ditional dose of their study drug at the time of PCI, i.e. 300 
mg of clopidogrel, at the investigator’s discretion, or 90 mg of 
ticagrelor for patients who were undergoing PCI more than 24 
hours after randomization. In patients undergoing CABG, it 
was recommended that the study drug be withheld — in the 
clopidogrel group, for 5 days, and in the ticagrelor group, for 
24 to 72 hours. Treatment continued for up to 12 months and 
the patients were followed at 1, 3, 6, 9 and 12 months.
These medications were compared over the primary ef-
ficacy end point of time to first occurrence of death from 
vascular causes, myocardial infarction, or stroke. The principal 
secondary efficacy end point was the primary efficacy variable 
studied in the subgroup of patients for whom invasive manage-
ment was planned at randomization while other composite end 
points served as additional secondary end points evaluated in 
the whole study population. The primary safety variable was 
major bleeding as defined in the study protocol. Over 18000 
patients were enrolled and the primary efficacy end point 
incidence was significantly lower in the ticagrelor than in the 
clopidogrel group (9.8% vs. 11.7% at 12 months p<0.001). This 
difference was apparent within the first 30 days of therapy 
and persisted throughout the study period. The secondary 
efficacy variables also occurred less often in the ticagrelor 
treated patients, as did the individual components of death 
from vascular causes and myocardial infarction, but not of 
stroke. These beneficial effects were seen in both ST elevation 
and non-ST elevation ACS group of patients and they were 
independent of the invasive or non-invasive strategy planned. 
However, in the small cohort of patients from North America 
(n = 1,814) ticagrelor was not found superior to clopidogrel, a 
finding likely being related to the small sample size.
No statistically significant differences were noted in terms 
of major, life-threatening or fatal bleeding. Hemorrhagic com-
plications related to by-pass surgery were similar in frequency, 
but those not related to by-pass surgery were higher in rate in 
the ticagrelor group, estimated either according to the study 
criteria (4.5% vs. 3.8%, p = 0.03) or the TIMI criteria (2.8% 
vs. 2.2%, p = 0.03). Ticagrelor was also associated with more 
episodes of intracranial bleeding (26 [0.3%] vs. 14 [0.2%], p 
= 0.06), including fatal intracranial bleeding (11 [0.1%] vs. 1 
[0.01%], p = 0.02) although with fewer episodes of other types 
of fatal bleeding (9 [0.1%], vs. 21 [0.3%]; p = 0.03). 16
In 13408 of the patients recruited in the PLATO trial, an 
invasive therapeutic approach was chosen. In this particular 
group, in accordance with the whole study population, the 
primary and secondary composite endpoints occurred in a 
smaller proportion of patients randomized on ticagrelor than 
clopidogrel (primary end point: 9% vs 10.7%, p=0.0025). 
Rates of death resulting from cardiovascular causes and of 
myocardial infarction were lower in the ticagrelor group, 
whereas rates of stroke did not differ between the groups. 
Total mortality rate was significantly reduced in the ticagrelor 
versus the clopidogrel group (3.9% vs 5.0%, p=0.0103). As far 
as safety endpoints are concerned, non by-pass surgery-related 
major or minor bleeding was the only significantly different 
variable, with ticagrelor associated with more haemorrhagic 
complications (8.9%7.1%, p=0.0004). 17
N O N - B L E E D I N G  A D V E R S E  E F F E C T S
Non-bleeding side effects were only seldom observed in 
all clinical trials. Interestingly, dyspnea was quite frequent. In 
ONSET/OFFSET trial dyspnoic phenomena attributed to the 
drug occurred in 25%, 4%, and 0% of patients in the ticagrelor, 
clopidogrel, and placebo groups, respectively (ticagrelor versus 
clopidogrel p=0.01). Three patients in the ticagrelor group 
stopped the study drug due to dyspnea. In the DISPERSE 
trial nonspecific symptoms, such as headache, were common. 
Nausea, dyspepsia, and hypotension seemed more common 
among ticagrelor recipients as was dyspnea (Table 2). Of those 
who reported dyspnea, 27% of the patients had resolution of 
this symptom within 24 h, 25% had resolution of the dyspnea 
after 24 h and 48% experienced persistent symptoms during 
treatment (>15 days). As expected, PLATO trial confirmed 
this observation. Dyspnea was more common in the ticagrelor 
group than in the clopidogrel group (13.8% vs 7.8%). An im-
mune-mediated mechanism has been proposed to explain this 
adverse reaction. Although this suggestion has been contra-
dicted, it seems that the immune conflict between the hostile 
platelet receptors subjected to the reversible blockade by the 
antiplatelet agent may lead to mild episodes of thrombotic 
thrombocytopenic purpura and consequent fluid retention 
contributing to dyspnea. Furthermore, as an ATP modified 
molecule, AZD 6140 can be metabolized to adenosine and 
cause bradycardia or trigger dyspnea especially in cases of 
airway hyper-reactivity.18
In the same study, there was also a higher incidence of 
ventricular pauses in the ticagrelor group in the first week, but 
not at day 30. Pauses were rarely associated with symptoms 
and the two treatment groups were not significantly different 
in terms of the incidence of syncope or the pacemaker im-
plantation rate. Ticagrelor intake was associated with a mild 
increase in creatinine and uric acid levels.18,19
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C O N C L U S I O N
Ticagrelor is a novel non-thienopyridine inhibitor of the 
P2Y12 ADP platelet receptor, which binds reversibly to its 
ligand allowing platelets to almost fully regain their activity 
within 3 days after therapy discontinuation. It also achieves 
rapid onset of action due to its rapid absorption and pharma-
cokinetics and is a powerful antiplatelet agent, more potent 
than the well-established thienopyridine clopidogrel. Initial 
studies as well as the large phase III PLATO trial have shown 
that ticagrelor use in acute coronary syndromes is associated 
with better outcomes with respect to all cause mortality, 
cardiovascular death and myocardial infarction, without a 
concomitant increase in major bleeding complications with the 
exception of intracranial hemorrhage which was more frequent 
although the absolute numbers were small. The relatively rapid 
cessation of ticagrelor’s action after its withdrawal would make 
it suitable in cases where an open-heart surgery is anticipated. 
However, by-pass surgery related bleeding showed only a trend 
towards reduction with ticagrelor compared to clopidogrel, 
which did not reach statistical significance. Moreover, extrapo-
lation of the results from PLATO trial to other indications for 
clopidogrel monotherapy, such as stroke, or peripheral arte-
rial disease, is premature. Ticagrelor’s usefulness in patients 
undergoing elective stenting is also undetermined so far and 
finally, concomitant use of fibrinolytic agents is another issue 
that needs to be addressed particularly in view of the associ-
ated increase in intracranial bleeding and taking into account 
that patients undergoing fibrinolysis were excluded from 
PLATO. Thus, although the results from the initial trials are 
encouraging, further analyses of the PLATO data may offer 
more insight into the efficiency of this antiplatelet agent in 
specific subgroups of patients. More studies both in pharma-
cogenomics and in of ticagrelor will be necessary before this 
drug establishes its role in modern antiplatelet therapy.
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